Researchers at the University of Bristol are using a new technique to develop a vaccine against Group A Streptococcus (GAS). Scientists at the University of Bristol are using a new technique to develop a vaccine against...
COVID-19 vaccines are effective against severe cases of the disease in children and adolescents, according to a review. However, with most children now having caught the SARS-CoV-2 virus and building up a natural...
Every year, hundreds of thousands of people in West Africa become infected with Lassa virus, which can cause Lassa fever and lead to severe illness, long-term side effects or death. There are currently no widely...
Malaria is one of the most important public health concerns in the world. According to the latest WHO World Malaria Report, there were 247 million cases of malaria in 2021 compared to 245 million cases in 2020. The...
Scientists at the University of Georgia say they’ve developed a vaccine that should be able to protect against a variety of dangerous fungi. In animal studies, the vaccine prevented severe infections and deaths from...
New inoculation based on Ebola VSV vaccine concept. A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus...
A three-dose regimen of a whole-parasite vaccine against malaria – called Plasmodium falciparum sporozoite (PfSPZ) vaccine – demonstrated safety and efficacy when tested in adults living in Burkina Faso, West Africa...
An experimental mRNA-based vaccine against all 20 known subtypes of influenza virus provided broad protection from otherwise lethal flu strains in initial tests, and thus might serve one day as a general preventative...
A new systematic review of animal studies testing a vaccine for tuberculosis raises questions about whether the studies provided sufficient evidence to move into trials of children. The new vaccine was a virus...
The Advisory Committee on Immunization Practices has updated its vaccination recommendations for immunocompetent adults aged 65 years or older to extend the interval between receipt of the Prevnar 13 and Pneumovax 23...